Ultragenyx Pharmaceutical (RARE) Income from Continuing Operations (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Income from Continuing Operations of 185000000.0 for Q1 2026, down 22.52% year-over-year from 238760683.76 in Q1 2025, and down 43.91% quarter-over-quarter from 128556000.0 in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 14 years of Income from Continuing Operations data on file, last reported at 185000000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 185000000.0, down 22.52% year-over-year; the trailing twelve-month figure through Mar 2026 was 608920000.0 (down 4900.69% YoY), and the FY2025 annual result was 575000000.0, down 8114.29% from the prior year.
- Income from Continuing Operations slipped to 185000000.0 in Q1 2026 per RARE's latest filing, from 128556000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 428798000.0 in Q4 2024 and troughed at 245106000.0 in Q3 2022.
- A 5-year average of 122528294.12 and a median of 153473000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations slumped 235.77% in 2022, then soared 447.06% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 153473000.0 in 2022, then gained by 19.5% to 123551000.0 in 2023, then soared by 447.06% to 428798000.0 in 2024, then slumped by 129.98% to 128556000.0 in 2025, then tumbled by 43.91% to 185000000.0 in 2026.
- Business Quant data shows RARE's Income from Continuing Operations at 185000000.0 in Q1 2026, 128556000.0 in Q4 2025, and 180413000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn | -185.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -185.00 Mn |
| Dec 31, 2025 | -128.56 Mn |
| Sep 30, 2025 | -180.41 Mn |
| Jun 30, 2025 | -114.95 Mn |
| Mar 31, 2025 | -151.00 Mn |
| Dec 31, 2024 | 428.80 Mn |
| Sep 30, 2024 | -133.52 Mn |
| Jun 30, 2024 | -131.60 Mn |
| Mar 31, 2024 | -170.68 Mn |
| Dec 31, 2023 | -123.55 Mn |
| Sep 30, 2023 | -159.65 Mn |
| Jun 30, 2023 | -159.83 Mn |
| Mar 31, 2023 | -163.97 Mn |
| Dec 31, 2022 | -153.47 Mn |
| Sep 30, 2022 | -245.11 Mn |
| Jun 30, 2022 | -158.16 Mn |
| Mar 31, 2022 | -152.32 Mn |
| Dec 31, 2021 | -124.79 Mn |
| Sep 30, 2021 | -73.00 Mn |
| Jun 30, 2021 | -122.43 Mn |